Acute Coronary Syndrome

• Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
• Acute Myocardial Infarction Toolkit
• Diabetes Optimal Care Cardiovascular Risk Reduction (DOC-CARE) EHR “MY CHART”
• Heart Disease: Resources for Individuals and Patients
• Acute coronary syndromes
• 2020 ESC NSTE-ACS Guidelines: Evolving Approaches and Recommendations
• 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
• IMPROVE-IT Trial: ACC 2015
• 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

Atherothrombosis

• DAPT PEGASUS and TRA 2P Trials Primary Efficacy and Safety Outcomes
• 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
• Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial
• Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
• Coagulation factor Xa (recombinant), inactivated-zhzo Prescribing Information
• 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee
• Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
• Management of bleeding in patients receiving direct oral anticoagulants
• Resources to support Joint Commission Accredited organizations implementation of: Reduce the likelihood of patient harm associated with the use of anticoagulant therapy
• Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Cardiac Imaging

• 2021AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
• Selecting the optimal cardiac stress test
• Cardiac Stress Testing: Choosing the Right Test and When

Dyslipidemia

• Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
• An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
• ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
• HPS3/TIMI55-REVEAL: Long-term Safety and Efficacy of Anacetrapib
• ROSE Study: Obicetrapib and High-Intensity Statin Therapy
• Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
• 2018 Guideline on the Treatment of High Blood Cholesterol: Education for Clinicians
• Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
• Bempedoic Acid for LDL-C Lowering: What Do We Know?
• Heart Disease and Stroke Statistics—2021 Update
• Identification of female-specific risk enhancers throughout the lifespan of women to improve CVD prevention
• The ABCs of Primary Cardiovascular Prevention: 2019 Update
• Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
• Improving the Cardiovascular Health of Women in the Nation
• Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
• Epidemiology of Dyslipidemia and Economic Burden on the Healthcare System
• Prescribing Information for Alirocumab
• Prescribing Information for Evolocumab
• Diabetic Dyslipidemia: Causes and Consequences
• 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
• ACC Statin Intolerance Tool
• 2017 NLA Expert Panel on Treatment with PCSK9 Inhibitors
• 2017 NLA Expert Panel on Treatment with PCSK9 Inhibitors – Infographic
• PCSK9 Inhibitor Access Barriers – Issues and Recommendations
• Current Indications, Cost, and Clinical Use of Anti-PCSK9 Monoclonal Antibodies
• NLA Recommendations for Patient-Centered Management of Dyslipidemia
• Patient Information: Reduce Your Risk of Heart Attack and Stroke
• High Cholesterol Educational Materials for Patients

Familial Chylomicronemia Syndrome (FCS)

• Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
• Burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study
• Understanding FCS – for Patients
• About FCS
• 2015-2020 Dietary Guidelines
• Medications that Increase Triglycerides
• FCS References
• What is FCS?

Familial Hypercholesterolemia (FH)

• Diagnostic Criteria for Familial Hypercholesterolemia
• Familial Hypercholesterolemia: Cardiovascular Risk Stratification and Clinical Management
• Learning About Familial Hypercholesterolemia

Heart Failure (HF)

• Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week
• Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
• Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
• Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
• Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial
• Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
• PARADIGM-HF Trial of Sacubitril/Valsartan
• Ivabradine in Heart Failure
• A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock
• Cardiac Calcitropes, Myotropes, and Mitotropes
• Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials
• Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
• Heart Failure: Patient Education

Hypertension

• CDC Facts About Hypertension
• Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparison, Reflections, and Recommendations
• 2017 Guideline for High Blood Pressure in Adults
• High Blood Pressure Information for Patients
• Treatment of resistant hypertension
• Million Hearts® Hypertension Control: Action Steps for Clinicians
• Systolic Blood Pressure Intervention Trial (SPRINT)

Hypertriglyceridemia

• Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
• Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
• REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
• 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
• Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
• National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
• Infographic: Use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
• REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. AHA 2018.
• Hypertriglyceridemia and atherosclerosis
• Hypertriglyceridemia and omega-3 fatty acids: Their often-overlooked role in cardiovascular disease prevention
• Fish and Omega-3 Fatty Acids

Hypertrophic Cardiomyopathy (HCM)

• 2024 AHA/ACC/Multisociety Guideline for the Management of HCM
• Mavacamten Prescribing Information
• Mavacamten REMS (Risk Evaluation and Mitigation Strategy)
• Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
• VALOR-HCM: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
• Risk Stratification in HCM
• Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review
• Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy
• Patient Information: Hypertrophic Cardiomyopathy (HCM)
• Hypertrophic Cardiomyopathy Association (HCMA)
• HCM Patient Discussion Checklist
• Patient Information: Hypertrophic Cardiomyopathy (HCM)
• Encouraging Share Decision Making in HCM
• Patient Info: HCM Action Plan
• Patient Info: HCM Fact Sheets
• Patient Info: HCM Genetic Testing
• Patient Info: Hypertrophic Cardiomyopathy

Lipoprotein (a) [Lp(a)]

• A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice
• Use of Lipoprotein(a) in Clinical Practice Infographic
• Patient Resource: What is Lipoprotein(a)?
• Patient Resource: Treating High Lp(a)
• Assessing Risk: Infographic on Lp(a) Screening
• Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
• Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease

Venous Thromboembolism (VTE)

• American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
• Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
• What is Venous Thromboembolism (VTE)?
• Antithrombotic Therapy for VTE Disease
• Wells’ Criteria for Pulmonary Embolism